Sunshine Biopharma
SBFM
1 hedge funds and large institutions have $262K invested in Sunshine Biopharma in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
0.8% less ownership
Funds ownership: 2.6% → 1.8% (-0.8%)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $53K
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$29K |
| 2 |
Two Sigma Securities
New York
|
-$13K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$11K |
SBFM Hedge Fund Activity: Q4 2022 in Review
1 of the 6,245 institutional investors tracked by Wall St. Rank reported a position in Sunshine Biopharma (SBFM) for Q4 2022, worth a combined $262K — down 23% from $341K a quarter earlier.
Fund positioning in SBFM was balanced in Q4 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Two Sigma Investments, cutting an estimated $29K.
- 1 institutional investor held Sunshine Biopharma (SBFM) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $262K of Sunshine Biopharma stock for Q4 2022, down 23% quarter-over-quarter.
- 0 funds opened new Sunshine Biopharma positions in Q4 2022 and 0 closed out.
- The largest Sunshine Biopharma seller in Q4 2022 was Two Sigma Investments, an estimated $29K sold.
Based on aggregated 13F filings for Q4 2022.